Rheumatoid Arthritis-associated Interstitial Lung Disease Definition

Multi-centric Prospective and Observational Study of Prevalence and Incidence of Interstitial Lung Diseases in Patients With Rheumatoid Arthritis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06184893

Acronym

RAID

Enrollment

250

Registered

2023-12-28

Start date

2023-11-20

Completion date

2025-10-31

Last updated

2023-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis-Associated Interstitial Lung Disease

Keywords

rheumatoid arthritis, rheumatoid arthritis-associated interstitial lung disease, interstitial lung disease

Brief summary

This is a prospective multicenter study in southern Belgium to determine the prevalence and incidence of interstitial lung disease in patients with rheumatoid arthritis (RA).

Detailed description

This is a prospective multi-centric longitudinal study of the prevalence and incidence of pulmonary diseases in patients with RA. During one year, patients with a RA diagnosis (according to the criteria of the American Society of Rheumatology) in the south of Belgium will be enrolled on a voluntary basis. If available, data including quality of life and symptoms questionnaires, medical examinations, 6-minute walk-tests, pulmonary function tests and chest CT will be collected during two years. Furthermore, patients could be included (if available data) in two additional sub-cohorts: * RAIDbio sub-cohort studying biomarkers: volatile organic compounds, induced sputum and blood biomarkers; * RAIDomix sub-cohort studying radiomic patterns (based on high resolution computed tomography of the chest). Due to a non-specific and poor clinical expression at beginning, there is currently an under-diagnosis of rheumatoid arthritis associated-interstitial lung disease (RA-ILD) at an early stage and we assume that an annual pneumological follow-up, search of early biomarkers and a radiomic approach of RA patients will overcome this issue. This should lead to a better follow-up and management (including the use of anti-fibrotic therapies in the future) of these patients and ultimately to a decrease in morbidity and mortality.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Diagnosis of rheumatoid arthritis according to the criteria of the American Society of Rheumatology * Age \> 18 years * Willing to participate in the study and sign the informed consent form (ICF) of participants or their legal authorized representative * RAIDbio subcohort : available data for one of the following analysis of biomarkers: volatile organic compounds, induced sputum or blood markers * RAIDomix : available data for high resolution computed tomography of the chest

Exclusion criteria

none

Design outcomes

Primary

Measure	Time frame	Description
Prevalence and incidence	2-5 years	To determine real-life prevalence and incidence of lung diseases in all patients with RA in South of Belgium

Secondary

Measure	Time frame	Description
Early diagnosis	2-5 years	To diagnose RA-ILD at an earlier stage
Morbidty/mortality	2-5 years	To decrease the morbidity and mortality associated with RA-ILD
Biomarkers	2-5 years	To identify specific early biomarkers of RA-ILD
Radiomics	2-5 years	To evaluate the prognosis value of radiomics approach in RA-ILD

Countries

Belgium

Contacts

Primary ContactJulien Guiot, PhD

j.guiot@chuliege.be00324/323 7881

Backup ContactAnna Denis, MD

anna.denis@chulige.be00324/323 7881

Outcome results